強気
$155.23
シナリオ価格
$139.940
+4.492 (+3.21%)終値時点
Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others.
Currently, Novanta Inc. (NOVT) is not a good buy. The stock is trading at $128.79, significantly below its analyst price target of $194, but recent performance shows a concerning RSI of 24.523, indicating oversold conditions. Additionally, insider selling has increased by 134.30% over the last month, which raises red flags about management's confidence in the company's near-term prospects. The stock has also seen a 5-day change of -8.84%, suggesting negative momentum. The main risk is the high P/E ratio of 82.54, indicating that the stock may be overvalued compared to its earnings potential.
Baird
$194
2026-08-07
Baird
2026-08-07
目標株価
$194
Baird
$173
2026-05-13
Baird
2026-05-13
目標株価
$173
Baird
$144
2026-03-30
Baird
2026-03-30
目標株価
$144
Baird
$150
2026-02-25
Baird
2026-02-25
目標株価
$150
Baird
$133
2025-08-11
Baird
2025-08-11
目標株価
$133
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

Novanta Executives to Present at Baird 2026 Global Industrial Conference

Novanta to Release Q3 2026 Results and Host Conference Call

Novanta Executives to Present at Baird Global Healthcare Conference

Novanta (NOVT) Q2 2026 Earnings Call Transcript

Novanta to Release Q2 2026 Results and Host Conference Call
Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others. It operates in the Technology sector (MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SU industry).
Currently, Novanta Inc. (NOVT) is not a good buy. The stock is trading at $128.79, significantly below its analyst price target of $194, but recent performance shows a concerning RSI of 24.523, indicating oversold conditions. Additionally, insider selling has increased by 134.30% over the last month, which raises red flags about management's confidence in the company's near-term prospects. The stock has also seen a 5-day change of -8.84%, suggesting negative momentum. The main risk is the high P/E ratio of 82.54, indicating that the stock may be overvalued compared to its earnings potential.
1 analysts cover NOVT: 1 rate it Buy, 0 Hold and 0 Sell.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。